These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1084 related articles for article (PubMed ID: 16050785)

  • 21. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
    Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
    J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
    Frampton JE
    Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.
    Markovic A; Chung CH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1149-59. PubMed ID: 23098115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
    Loeffler-Ragg J; Schwentner I; Sprinzl GM; Zwierzina H
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1517-31. PubMed ID: 18808311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
    Caponigro F
    Anticancer Drugs; 2004 Apr; 15(4):311-20. PubMed ID: 15057134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
    Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Hitt R; Irigoyen A; Cortes-Funes H; Grau JJ; García-Sáenz JA; Cruz-Hernandez JJ;
    Ann Oncol; 2012 Apr; 23(4):1016-22. PubMed ID: 21865152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab: its use in combination with radiation therapy and chemo-therapy in the multimodality treatment of head and neck cancer.
    Wagner TD; Yang GY
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):76-83. PubMed ID: 18537749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
    Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
    Wheeler S; Siwak DR; Chai R; LaValle C; Seethala RR; Wang L; Cieply K; Sherer C; Joy C; Mills GB; Argiris A; Siegfried JM; Grandis JR; Egloff AM
    Clin Cancer Res; 2012 Apr; 18(8):2278-89. PubMed ID: 22351687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
    Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
    Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Seiwert TY; Fayette J; Cupissol D; Del Campo JM; Clement PM; Hitt R; Degardin M; Zhang W; Blackman A; Ehrnrooth E; Cohen EEW
    Ann Oncol; 2014 Sep; 25(9):1813-1820. PubMed ID: 24928832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.
    Bahassi el M; Li YQ; Wise-Draper TM; Deng L; Wang J; Darnell CN; Wilson KM; Wells SI; Stambrook PJ; Rixe O
    Eur J Cancer; 2013 Jul; 49(10):2345-55. PubMed ID: 23578570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
    Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
    J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.
    Reuter CW; Morgan MA; Eckardt A
    Br J Cancer; 2007 Feb; 96(3):408-16. PubMed ID: 17224925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.